Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...

The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...

This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr ...

GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes. For many patients, the drugs remain a highly effective ...

A patient checks in and sits down, closer to their own health than they will be at almost any other point in the year, turning over the questions they mean to ask, the decision they're about to make.

The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...

Governance pressure is intensifying at Novartis, with calls to penalize dealmakers for failed M&A and align executive pay ...

For more than 20 years now, companies in the life sciences industry have waved the banner of patient-centricity, spending on advisory boards, listening sessions and even “patient weeks” in their ...

Dr. Elena Christofides is a practicing endocrinologist and scientific/medical advisor to Sparrow Pharmaceuticals. Dr. Elena Christofides on why the overnight dexamethasone suppression test is the only ...

Dr. Elena Christofides on why the overnight dexamethasone suppression test is the only cortisol screen that actually identifies HPA dysfunction. GLP-1 medications might be most well-known as ...

Carl Valenstein is a partner with Morgan Lewis and co-leads the firm’s Environmental, Social, and Governance (ESG) & Sustainability team. Shabeena Sharak, a summer associate with the firm, contributed ...

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...